Douglas Lowy Named Acting Director of the National Cancer Institute
News Apr 07, 2015
Douglas Lowy, M.D., was officially named the National Cancer Institute’s (NCI) Acting Director. NCI is one of the 27 Institutes and Centers that comprise the National Institutes of Health. Lowy has served as NCI’s deputy director since July 2010, helping lead NCI’s key scientific initiatives since that time.
Dr. Lowy, a cancer researcher for more than 40 years, received the National Medal of Technology and Innovation from President Obama in 2014 for his research that led to the development of the human papillomavirus (HPV) vaccine.
As chief of the Laboratory of Cellular Oncology in the Center for Cancer Research at NCI, Lowy’s research includes the biology of papillomaviruses and the regulation of normal and neoplastic growth.
His laboratory, in close collaboration with John T. Schiller, Ph.D., was involved in the initial development, characterization, and clinical testing of the preventive virus-like particle-based HPV vaccines that are now used in the three U.S. Food and Drug Administration-approved HPV vaccines.
“We are fortunate to have a scientist of such stature stepping into the role of Acting Director of the NCI,” said NIH Director Francis S. Collins, M.D., Ph.D. “Dr. Lowy possesses not only a sharp intellect, deep knowledge of science, and proven leadership experience, but he takes a warm and humane approach to all things. He is superbly positioned to lead the NCI at a time of exceptional progress in cancer research.”
Dr. Lowy is a member of the National Academy of Sciences (NAS), as well as the Institute of Medicine of the NAS. For their pioneering work, Lowy and Schiller have received numerous honors in addition to the National Medal, including the 2011 Albert B. Sabin Gold Medal Award and the Federal Employee of the Year Award in 2007 from the Partnership for Public Service.
Lowy received his medical degree from New York University School of Medicine, New York City, and trained in internal medicine at Stanford University, California, and dermatology at Yale University, New Haven, Connecticut.
Radical New Approach to Vaccine Development Could Help Reduce Illness From FluNews
More than 700,000 Americans were hospitalized due to illnesses associated with the seasonal flu during the 2014-15 flu season, according to federal estimates. A radical new approach to vaccine development at UCLA may help lower that figure for future flu seasons.READ MORE
Pioneering Method Enables Screening Millions of Human Antibodies for Rapid Therapeutic DiscoveryNews
A paper just published in Nature Biotechnology outlines a pioneering method of screening a person's diverse set of antibodies for rapid therapeutic discovery.READ MORE